



US GENERICS:

MONTHLY PRICE CHANGES – JULY 2024



☎ +91 94997 68112

✉ nimish@researchdelta.com

06 Aug 2024

ABOUT THE REPORT

- The report highlights annual price changes in various dosage forms with monthly breaks – only for generic drugs
- The price reflects NADAC pricing as reported by Centers for Medicare / Medicaid Studies
- It covers ~60% of the ANDAs in the market

EXECUTIVE SUMMARY

- After a steep MoM increase of ~13% in aggregate pricing in June 2024, July witnesses a drastic decline of ~13%.
- After change in methodology in April 2024, NADAC has become highly volatile and not reflecting the correct ground situation.
- As per the CMS, the decline in April were due to increased pharmacy participation in the monthly pricing survey. However, reasons for the volatility post April is not explained by CMS.
- There is no change in numbers of products covered under NADAC.
- All in all, we believe, we will have to give some time to the NADAC data to smoothen as it currently is influenced by change in coverage of pharmacies and drugs.


ORAL SOLIDS & LIQUIDS

MoM Price change




INJECTABLES

MoM Price change




INHALATION PRODUCTS

MoM Price change




OPHTHALMIC / OTIC

MoM Price change




TOPICALS

MoM Price change




TRANSDERMAL

MoM Price change




DENTAL PRODUCTS

MoM Price change



OTHERS

MoM Price change



OVERALL INDUSTRY

MoM Price change



DOSAGE WISE UNIVERSE

Route Of Administration	No of ANDA
Injection	339
Topical	545
Oral	4693
Inhalation	122
Ophthalmic / Otic	195
Others	51
Transdermal	52
Dental	8
Total	6005

ANNEXURE 1: ROUT OF ADMINISTRATION CONSIDERED AS OTHERS

Route Of Administration

RECTAL

IRRIGATION

VAGINAL

PERFUSION,CARDIAC

IMPLANTATION

RECTAL,SUBLINGUAL

INJECTION,ORAL

INTRAVENOUS,ORAL

INJECTION,ORAL,RECTAL

INTRAPLEURAL

INTRACRANIAL

IONTOPHORESIS,TOPIICAL

INHALATION,INTRAVENOUS

INTRADERMAL

INTRAMUSCULAR,ORAL

THANK
YOU

